Human immunodeficiency virus type 1 hypersusceptibility to amprenavir in vitro can be associated with virus load response to treatment in vivo.
The human immunodeficiency virus type 1 protease mutation N88S, which is occasionally selected by treatment with nelfinavir or indinavir, confers hypersusceptibility to amprenavir in vitro. The clinical relevance of this observation is unclear. We report a case of N88S developing after virologic failure of both indinavir- and nelfinavir-containing regimens that was managed successfully with a regimen that contained amprenavir.
Zachary
K C
KC
Infectious Disease Division, Massachusetts General Hospital, Partners AIDS Research Center, and Harvard Medical School, Boston, MA 02114, USA. kzachary@partners.org
Hanna
G J
GJ
D'Aquila
R T
RT
D000328:Adult; D019943:Amino Acid Substitution; D002219:Carbamates; D004352:Drug Resistance, Microbial / Q000235:genetics*; D005663:Furans; D015658:HIV Infections / Q000188:drug therapy / Q000821:virology; D016333:HIV Protease / Q000235:genetics* / Q000378:metabolism; D017320:HIV Protease Inhibitors / Q000494:pharmacology* / Q000627:therapeutic use; D015497:HIV-1 / Q000187:drug effects* / Q000201:enzymology / Q000235:genetics; D006801:Humans; D008297:Male; D009154:Mutation; D013449:Sulfonamides / Q000494:pharmacology* / Q000627:therapeutic use; D019562:Viral Load
D002219:Carbamates; D005663:Furans; D017320:HIV Protease Inhibitors; D013449:Sulfonamides; C095108:amprenavir; D016333:HIV Protease